Bioventus Inc.
NASDAQ:BVSMedical - Devices
+$0.18 today
- Market cap
- $727.20M
- Beta
- 0.67
- P/E (TTM)
- 20.6
- EPS (TTM)
- $0.42
Volume 0.70M
Average 0.56M
BVS Interest Expense
Cost of servicing the company's debt during the period.
Bioventus Inc.NASDAQ: BVS
Interest Expense · Q1 FY2026 · quarter ended Mar 2026
Interest expense declines year over year
Q1 FY2026 interest expense of $4.33M fell 42.4% year over year, behind the -35.2% change in trailing-twelve-month interest expense. Sequentially, it fell 18.5% from the prior quarter. Over 3 fiscal years it compounded at +30.1% a year.
Context
- Interest expense amounted to 4.7% of revenue in FY2025, down 2.1 pp from a year earlier.
- Interest expense increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -42.4% toward the trailing-twelve-month pace of -35.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Expense history
USD · from the income statement
- Latest · FY2025
- 26.49M USD
- Year-over-year change
- -31.7%
- 4-year CAGR
- +120.9%
| Period | Period end | Interest Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 26.49M | -31.7% |
| FY2024 | 2024-12-31 | 38.79M | -4.6% |
| FY2023 | 2023-12-31 | 40.68M | +238.4% |
| FY2022 | 2022-12-31 | 12.02M | +981.0% |
| FY2021 | 2021-12-31 | 1.11M | — |
Interest Expense vs competitors
How BVS compares with its peers on the latest reported figures
- BVS's LTM Mar 2026 interest expense of $23.3M is the 3rd highest of the 9 companies compared; the peer median is $3.04M.
- Its year-over-year change of -35.2% is the 5th highest of 8, against a peer median of -31.3%.
- Interest expense amounts to 4.0% of revenue for BVS, versus a peer median of 2.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | $141.33M | -5.8% | +20.9% | 2.3% | |
| LTM Mar 2026 | $94.29M | +22.1% | +20.3% | 5.7% | |
| LTM Mar 2026 | $23.3M | -35.2% | +30.1% | 4.0% | |
| LTM Mar 2026 | $18.65M | -37.0% | +138.6% | 2.3% | |
| LTM Mar 2026 | $3.23M | -26.2% | +29.5% | 2.6% | |
| LTM Jun 2026 | $2.86M | -43.2% | +9.0% | 3.6% | |
| LTM Mar 2026 | $2.07M | -31.3% | -29.2% | 0.5% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding BVS) | $3.04M | -31.3% | +20.6% | 2.3% | |
Competitors are the stored peer set for BVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 430.9M | 512.12M | 512.35M | 573.28M | 568.09M |
| Cost of Revenue | 128.19M | 181.04M | 184.15M | 185.05M | 185.66M |
| Gross Profit | 302.71M | 331.08M | 328.19M | 388.23M | 382.43M |
| Gross Margin | 70.3% | 64.6% | 64.1% | 67.7% | 67.3% |
| Research & Development | 19.04M | 23.85M | 13.45M | 13.64M | 12.11M |
| Selling, General & Admin | 254.25M | 332.13M | 303.88M | 327.09M | 311.77M |
| Operating Expenses | 290.65M | 498.31M | 409.92M | 400.21M | 323.88M |
| Depreciation & Amortization | 34.88M | 55.4M | 57.37M | 49.56M | 47.01M |
| EBITDA | 45.48M | (121.61M) | (23.07M) | 39.22M | 99.21M |
| EBITDA Margin | 10.6% | -23.7% | -4.5% | 6.8% | 17.5% |
| Operating Income | 12.06M | (167.23M) | (81.73M) | (11.98M) | 58.55M |
| Operating Margin | 2.8% | -32.7% | -16.0% | -2.1% | 10.3% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.11M | 12.02M | 40.68M | 38.79M | 26.49M |
| Other Income / Expenses | (2.57M) | (21.79M) | (39.39M) | (37.15M) | (32.84M) |
| Income Before Tax | 9.49M | (189.03M) | (121.11M) | (49.13M) | 25.71M |
| Pre-Tax Margin | 2.2% | -36.9% | -23.6% | -8.6% | 4.5% |
| Income Tax Expense | (1.97M) | (44.37M) | 85K | (5.29M) | (1.57M) |
| Net Income | 19.38M | (158.7M) | (156.23M) | (33.54M) | 22.73M |
| Net Margin | 4.5% | -31.0% | -30.5% | -5.9% | 4.0% |
| EPS (Basic) | (0.15) | (2.59) | (2.49) | (0.52) | 0.34 |
| EPS (Diluted) | (0.15) | (2.59) | (2.49) | (0.52) | 0.33 |
| Weighted Avg Shares | 45.47M | 61.39M | 62.65M | 65.36M | 66.62M |
| Weighted Avg Shares (Diluted) | 45.47M | 61.39M | 62.65M | 65.36M | 68.91M |
Bioventus Inc.
NASDAQ:BVS
Intrinsic Alpha fair value
Locked
Current Price
$10.62
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.